Case Study: Early-Stage Asset ValuationAbout EVERSANA in APAC With our regional headquarters in Singapore and offices across Asia Pacific and worldwide, EVERSANATM provides integrated services and solutions to accelerate clinical and commercial success. We are constantly evolving and adapting to solve the complex challenges our Asia Pacific clients are facing in local and global markets.3 © 2020 EVERSANA. All Rights Reserved. CONFIDENTIAL. How Do You Assess The Value And Risk Of An Early-stage Asset Targeting An Auto- immune Disease? • JapanCo was developing a promising early-stage asset, Asset A1, for launch in an auto-immune disease in ten years. • The disease market was crowded, with fierce competition for price and share, especially with biosimilars, and a large development

Join for free to read